ArticleArchives of rehabilitation research and clinical translation2026
Exploring Treatment Expectations and Clinical Meaningfulness in Spinal Muscular Atrophy Using the Goal Attainment Scale.
Article in Archives of rehabilitation research and clinical translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate how Goal Attainment Scale (GAS) in spinal muscular atrophy (SMA) identifies patient-reported clinically meaningful improvement after disease-modifying treatment and to evaluate whether the patient-stated goals identified through GAS are already captured by items in existing motor assessment scales. Design: Longitudinal retrospective study considering the first available follow-up. Setting: The study was conducted in a rehabilitation center dedicated to neuromuscular diseases. Participants: The GAS was recorded from N=58 SMA patients on treatment with nusinersen or risdiplam regularly followed for clinical follow-up in 2023. Main Outcome Measures: Clinical and demographic data, SMA type, Hammersmith Functional Motor Scale, Children's Hospital of Philadelphia scale, Revised Upper Limb Module, 6 Minute Walk Test, and GAS questionnaire were collected. Results: One hundred forty-nine SMART goals were clustered in 15 macrodomains, with the most frequent being mobility, upper limb strength, and activities of daily living. Most smart goals (72%) could be redirected to items of standardized motor and functional scales. Unmet goals primarily involved activities of daily living, endurance, and mobility, with a particular focus on upper limb strength. Conclusions: The GAS provides an individualized, reliable, and quantifiable measure of goal attainment, and is useful in setting realistic treatment expectations that could guide patients and physicians to interpret changes over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.